Antisense oligonucleotides (ASOs) and RNA-based therapies represent a transformative approach to treating the underlying genetic and neurodegenerative diseases by targeting molecular causes of these conditions. These therapies work by modulating RNA expression, either by degrading disease-causing mRNA, correcting aberrant splicing, or blocking translation of toxic proteins. This page provides a comprehensive overview of ASO and RNA therapy mechanisms, clinical candidates, and therapeutic applications for Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative disorders.
Antisense oligonucleotides are short, synthetic single-stranded DNA sequences designed to bind specifically to target messenger RNA (mRNA) through Watson-Crick base pairing. Once bound, ASOs employ several distinct mechanisms to modulate gene expression:
The most common mechanism involves recruitment of RNase H, an endonuclease that specifically cleaves the RNA strand of RNA-DNA hybrids. When an ASO binds to its target mRNA, RNase H recognizes the hybrid duplex and cleaves the RNA, leading to rapid degradation of the transcript. This mechanism is particularly effective for reducing expression of gain-of-function mutations or overexpressed disease proteins.
ASOs can also modulate alternative splicing by binding to pre-mRNA and sterically blocking splice site recognition. This approach is valuable for diseases where aberrant splicing produces toxic protein isoforms. By masking or exposing specific splice sites, ASOs can restore normal splicing patterns or shift isoform ratios toward protective variants.
Some ASOs function as steric blocks without recruiting RNase H. These "gapmer" ASOs bind to mRNA and physically prevent ribosomes from translating the transcript into protein. This mechanism is useful when partial reduction of protein expression is desired.
The clinical utility of ASOs depends heavily on chemical modifications that enhance stability, tissue delivery, and target affinity while minimizing off-target effects:
| Modification | Description | Benefits |
|---|---|---|
| 2'-O-Methyl (2'-OMe) | Ribose sugar modification | Improved stability, reduced immunogenicity |
| 2'-O-Methoxyethyl (2'-MOE) | Extended sugar modification | Enhanced binding affinity, increased nuclease resistance |
| Locked Nucleic Acid (LNA) | Constrained sugar conformation | Very high binding affinity, single nucleotide specificity |
| Phosphorodiamidate Morpholino Oligomer (PMO) | Uncharged backbone | Excellent stability, reduced off-target effects |
| 2'-Deoxy, 2'-Fluoro | Sugar modification | Improved binding, RNase H activation |
| Phosphorothioate (PS) | Backbone modification | Nuclease resistance, protein binding |
| Conjugated peptides (Peptide Nucleic Acid - PNA) | Backbone replacement | High stability, sequence-specific binding |
Tofersen is an ASO designed to reduce superoxide dismutase 1 (SOD1) protein expression in patients with SOD1-linked familial ALS. The therapy binds to SOD1 mRNA, leading to RNase H-mediated degradation and subsequent reduction in toxic SOD1 protein[1][2].
Clinical Development:
ION363 targets the gene encoding fused in sarcoma (FUS) protein, which is mutated in some cases of familial ALS. By reducing FUS protein expression, this ASO aims to prevent FUS-related neurodegeneration.
Clinical Status: Phase 1/2 trials ongoing
ION717 is an ASO targeting MAPT mRNA, which encodes the tau protein that forms neurofibrillary tangles in Alzheimer's disease. By reducing tau expression, this therapy aims to slow or prevent tau-mediated neuronal death[3][4].
Development:
This is another tau-targeting ASO from Ionis that uses their advanced chemistry platform for enhanced brain delivery. The therapy is designed to reduce all forms of tau protein[3:1][4:1].
Originally developed by Ionis and later partnered with Roche, tominersen targets the huntingtin (HTT) gene to reduce mutant huntingtin protein. Although the Phase 3 GENERATION HD1 trial was discontinued due to unfavorable risk-benefit profile, the program provided valuable lessons about ASO dosing and delivery[5].
ASO approaches for Parkinson's disease target genes implicated in disease pathogenesis, including:
Clinical trials are in early stages for several of these programs.
Small interfering RNA (siRNA) molecules trigger the RNA interference (RNAi) pathway, leading to sequence-specific mRNA degradation. Unlike ASOs, siRNAs require delivery vehicles for cellular uptake.
Alnylam Pharmaceuticals has developed a proprietary GalNAc conjugation platform that enables subcutaneous delivery of siRNA to target hepatocytes. For CNS applications, the company is exploring:
Several siRNA programs targeting neurodegenerative disease genes are in development, though none have reached late-stage clinical trials for CNS indications as of 2024.
mRNA-based therapeutics offer the potential to deliver genetic instructions for therapeutic protein expression directly to cells. Applications in neurodegeneration include:
Delivering mRNA encoding missing or deficient proteins:
mRNA encoding therapeutic antibodies can be delivered to produce antibodies in vivo:
Advantages:
Challenges:
While not traditional RNA therapies, CRISPR-based approaches represent the next frontier in nucleic acid-based therapeutics:
Base editors enable single-nucleotide changes without double-strand breaks:
Prime editing offers greater flexibility for precise genome modifications, including insertions and deletions.
CNS delivery remains the major hurdle for CRISPR-based therapies
The most common route for CNS-directed ASOs, intrathecal injection delivers therapy directly to the cerebrospinal fluid, bypassing the blood-brain barrier:
Approved Examples:
Considerations:
Non-invasive approach that exploits the nose-to-brain pathway:
Combining ASO delivery with focused ultrasound-mediated BBB opening shows promise for enhancing brain penetration[6].
Leading developer of ASO therapies with multiple programs in neurodegeneration:
Partnered with Ionis on several CNS ASO programs:
Major partnership with Ionis for neurological disorders:
siRNA platform with growing CNS pipeline:
The BBB remains the primary challenge for CNS-directed RNA therapies. Strategies under development include:
Antisense oligonucleotide and RNA therapies represent a promising new frontier in neurodegenerative disease treatment. With the recent approval of tofersen for SOD1-ALS and multiple programs advancing in Alzheimer's, Parkinson's, and other disorders, these therapies are moving from promise to reality. Continued advances in chemistry, delivery technology, and biomarker development will be critical for realizing the full potential of RNA-based therapeutics for neurodegenerative diseases.
Kankowski S, et al. Antisense oligonucleotides for neurodegenerative disorders. Nat Rev Drug Discov. 2023. ↩︎ ↩︎
Bennett CF, et al. Antisense oligonucleotide therapeutics. Nat Rev Drug Discov. 2022. ↩︎ ↩︎
Finkel RS, et al. Nusinersen in spinal muscular atrophy. Lancet. 2017. ↩︎ ↩︎
Sullivan JM, et al. ASO therapy for Huntington's disease. N Engl J Med. 2021. ↩︎
Miller T, et al. Phase 1/2 study of tofersen for SOD1 ALS. N Engl J Med. 2023. ↩︎